Bruce Booth @LifeSciVC Twitter profile

Last Seen Profiles

@monaauraa

@jinhogi44683852

@ju6_rz

@ryuuga469

@PSinrapachai

@_mumunnn_

@psychepositive1

@v_rll8

@kanginkangin2

@acervododrive

@WorldDlt

@oyelewaa

@SkyborneLegacy

@hogsta_domstol

@sekumi7128

@PlanasHoll56391

@meicilemeicile

@choco_lyy

@jandakembangstw

@csxvanessa

@BaljitRihal

@o4PyE1Y1167L4

@AtPrimros

@Yasaman48149012

@TrainerBrew

@HolmwoodStella

@sd0107

@AprilClark28646

@OLrin_00

@TempleCollege

@BasketballDad27

@LoveAquaMoon

@sarahtfried

@ATLGreg1

@lion007

@KevinConnelly24

Bruce Booth

@LifeSciVC

5 years

Only in Cambridge: I’m stuck in traffic on the exit from the Pike and a biotech CEO pulls up next to me, rolls window down and says “Hey Bruce, we’ve got great NHP efficacy data... can’t wait to show you”... Made my commute far less painful! This ecosystem never ceases to amaze

23

40

694

Bruce Booth

@LifeSciVC

2 years

Biotech is just so small. $FB lost $200B yesterday due to metaverse investing... which is more than the combined pre-money valuations of the 360+ biotech IPOs since 2015. Trying to make a virtual world vs trying to make real medicines. Both are challenging, it seems.

20

106

650

Bruce Booth

@LifeSciVC

3 years

Waiving IP has consequences... slippery slope... now they say “do insulin next”? Let’s do PD1s after that because cancer is a global crisis... Then let’s do Alzheimer’s.. Oh wait, we have no drugs for AD yet... and nor will we if there are no patents or reward for innovating

Alexandria Ocasio-Cortez

@AOC

3 years

Let’s do insulin next

3K

34K

240K

60

68

562

Bruce Booth

@LifeSciVC

3 years

Personal Reflection: Empathy In The Workplace Life isn't always easy, and many of us have a lot going on underneath the facade, but its the emotional connectedness with others that makes all the difference. To those that have been there for me, thx you

Personal Reflection: Empathy In The Workplace - LifeSciVC

Just before I chaired a Board meeting last year, I spent a frustratingly painful hour going through many of the uncomfortable details of my divorce process and a set of emotional custody issues with...

lifescivc.com

52

59

514

Bruce Booth

@LifeSciVC

5 years

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference. More concerned than ever about the value of the JPM week and what it says about our industry. #JPM19 #JPMHC19

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference - LifeSciVC

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry. For context, by JPM I don’t mean the actual J.P. Morgan...

lifescivc.com

47

113

370

Bruce Booth

@LifeSciVC

4 years

In mild COVID-19 patients, placebo was similarly effective to HCQ in viral clearance. Randomized open label clinical trial (NCT04261517): in 30 mild patients, 93% cleared virus w/in 7 days on placebo (vs 87% with HCQ). h/t Umer Raffat at EvercoreISI

27

160

340

Bruce Booth

@LifeSciVC

3 years

Atlas Venture 2021 Year In Review Here's our "state of the industry" talk (that we just shared with our LP's at our Annual Meeting) exploring the macro issues & broader sector, diving into the biotech VC ecosystem, and providing a brief update on Atlas.

Atlas Venture Year In Review 2021

Atlas Venture partner and LifeSciVC author Bruce Booth shares his Year in Review of 2021. Recorded on October 26, 2021. Watch the talk here and visit www.atl...

www.youtube.com

12

47

328

Bruce Booth

@LifeSciVC

2 years

Here’s the Atlas Venture 2022 Year In Review. This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas

Atlas Venture Year in Review 2022 B. Booth

Atlas Venture partner and LifeSciVC author Bruce Booth shares his Year in Review of 2022.Recorded on November 2, 2022.00:00 Introduction00:25 Biotech Capital...

www.youtube.com

13

52

293

Bruce Booth

@LifeSciVC

3 years

Surprising stat: >50% of biotech's that IPO'd between 2000-2013 have had at least one product approved. 8% of those IPOs actually got 2 products approved. (Thx to Josh Schimmer at Evercore ISI)

12

48

291

Bruce Booth

@LifeSciVC

5 years

Biogen has lost more value this morning (~$17B) than was raised in all 130+ biotech IPOs since Jan 2015 combined (~$15B)... Ouch. $BIIB

16

128

281

Bruce Booth

@LifeSciVC

5 years

Venturing A Perspective On The Drug Pricing Debate. I've been largely quiet on this topic, but couldn't any longer. First principles of investin and what it means for pricing. Observations on the US system. And a few suggestions for policy emphasis.

27

104

274

Bruce Booth

@LifeSciVC

3 years

The Biotech Paradox of 2020: A Year In Review The striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. Surprisingly, in many ways 2020 was actually the best year ever for biotech.

9

77

257

Bruce Booth

@LifeSciVC

3 years

Happy holidays, Biotwitter! Despite the choppy markets, feeling great about the long term potential of innovation and this incredible biotech family…

9

1

258

Bruce Booth

@LifeSciVC

7 years

It took avg of 4.1 years in drug discovery in 1998. It takes 4.1 years now, nearly 20 years later (accdg to KMR). I'm both frustrated and puzzled by this - where's the "big impact" of massive increases in computational power on shortening drug discovery cycle times?

46

110

257

Bruce Booth

@LifeSciVC

3 years

This post exploded last night. Clarification: Insulin itself is generic. Out of pocket insulin costs are the issue, not because of IP, but insurance/PBM system failure Takehome: sentiment that you can solve drug availability/access by waiving IP is both wrong & anti-innovation

Bruce Booth

@LifeSciVC

3 years

Waiving IP has consequences... slippery slope... now they say “do insulin next”? Let’s do PD1s after that because cancer is a global crisis... Then let’s do Alzheimer’s.. Oh wait, we have no drugs for AD yet... and nor will we if there are no patents or reward for innovating

60

68

562

12

33

251

Bruce Booth

@LifeSciVC

3 years

10 years ago this month I started the LifeSciVC blog. Since March 2011, we’ve had 450 blog posts, 2M+ unique pageviews, and a broad range of “From The Trenches” perspectives from executives in our portfolio. Reflections on the past/future of the LifeSciVC media platform: 1/x

10

15

244

Bruce Booth

@LifeSciVC

3 years

Q: If reducing amyloid is approvable, why wouldn't $MRK revive verubecestat (BACE) for Accelerated Approval after it's "failed" Ph 3 studies? Showed striking amyloid reductions (60-80%), but no real cognitive benefit. How is that diff than Adu? This new precedent opens up path?

17

29

242

Bruce Booth

@LifeSciVC

2 years

Takeda Acquires Nimbus’ Tyk2 Autoimmune Program for up to $6B Congrats to @JebKeiper & the @NimbusTx team! Here's a blog on the Nimbus' journey - more to come in Chapter 3! Looking fwd to watching 4858's continued success in Takeda's capable hands

Takeda Acquires Nimbus' Tyk2 Autoimmune Program - LifeSciVC

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset...

lifescivc.com

26

30

243

Bruce Booth

@LifeSciVC

2 years

So many biotechs have been beaten down as the $XBI got crushed, 100s have negative EV's, mkt caps sub $100M and share prices in penny stock land... What are the best examples of #biotech companies that resurrected themselves? Sharing these to inspire some hopeful optimism :)

41

26

239

Bruce Booth

@LifeSciVC

3 years

Americans spent $15B during COVID on retail coffee. We spent over $8B on whiskey and tequila. As a country, we spent way less than that on COVID vaccines. In addition to saving countless lives, vaccines have been incredibly good value to society...

7

43

233

Bruce Booth

@LifeSciVC

4 years

If I get COVID, I really want the drug called Regeneron... It's a great drug... Makes you feel better today than you did 3 days ago. I've heard it does great things to great people in this great country of America. More Regeneron for everybody in the pandemic!

29

13

234

Bruce Booth

@LifeSciVC

5 years

Sharing our "Year In Review": Annual Talk On Macro, Biotech, and Atlas. A data-rich, whirlwind tour thru a bunch of pharma and biotech topics over about 45 min. Cheat sheet with timestamps included.

14

64

225

Bruce Booth

@LifeSciVC

4 years

My oldest just passed her driving test! So excited for her, so nerve-racking for me...

15

2

225

Bruce Booth

@LifeSciVC

4 years

Those crazy Wellesley kids with their edgy graffiti... #ScienceIsCool #STEM

13

17

223

Bruce Booth

@LifeSciVC

2 years

Huge #biotech rally since mid-June, $XBI up 35%+ Appears to be mostly a melt-up driven by short covering (analysis from Torreya Partners): Biggest gainers have had highest short interest. So while it’s good to see positive gains, we need more fundamental buyers & fund flows

9

40

222

Bruce Booth

@LifeSciVC

2 years

The aggregate enterprise value of the biotech sector is now down 64% since Feb 8, 2021 peak. The sector is trading well below where it was when the COVID hit. So much for Biopharma saving the world! (Thx to Torreya).

14

40

219

Bruce Booth

@LifeSciVC

3 years

Two major clinical milestones for new modalities in the past few days: The 1st in vivo CRISPR gene editing in TTR with 96% serum reductions by $NTLA The 1st placebo-controlled, healthy volunteer TPD study showing dose response to 90% target degradation by $KYMR 1/n

5

28

217

Bruce Booth

@LifeSciVC

3 years

Alzheimer’s is a horrible disease. Today a drug was approved that reduces amyloid. I wish there was more confidence that the drug really works on clinically meaningful endpoints, as these patients and families are desperate.

13

23

216

Bruce Booth

@LifeSciVC

8 months

2023 is almost over... we just finished our Annual Mtg with our LP's and our Atlas Retreat with industry leaders... so it's time to share. Here's our Atlas Venture 2023 "Year In Review" #Biotech @Atlasventure

Atlas Venture 2023 Year In Review - LifeSciVC

2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. Fortunately, despite all that, great...

lifescivc.com

5

50

208

Bruce Booth

@LifeSciVC

5 years

Just b/c Big Pharma externally sources >50% of their new programs doesn't mean they aren't investing in innovation.. R&D is team sport. W/o them as downstream partners for young biotechs, we'd b unable 2 advance drugs to mkt. They r essential players in the innovation ecosystem

STAT

@statnews

5 years

Opinion: Large pharmaceutical companies say that legislation in Congress to lower the cost of prescription drugs will hinder innovation. But our analysis shows they don't do much innovation.

9

32

52

10

46

212

Bruce Booth

@LifeSciVC

5 years

The Creation Of Biotech Startups: Evolution Not Revolution A response with historical context and a few counterpoints to the "biotech-should-be-more-like tech'' venture creation pieces by @ycombinator 's @snowmaker and @a16z 's @JorgeCondeBio .

The Creation Of Biotech Startups: Evolution Not Revolution - LifeSciVC

The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying...

lifescivc.com

16

84

211

Bruce Booth

@LifeSciVC

4 years

Biotech venture funding beats to a different drummer than most VC sectors. It's not sales metrics, it's experimental data around potential medicines. As long as programs advance to the key inflection points (R&D execution!) - data is the ultimate currency of progress & value

5

31

209

Bruce Booth

@LifeSciVC

5 months

Today we should celebrate the perseverance of $VRTX in translating the incredible human genetics of Nav 1.8 for pain into a drug with Phaase 3 data ready for approval. The commercial market can debate the differentiation and merits vs existing generics, but it should be a huge

8

17

206

Bruce Booth

@LifeSciVC

6 months

Surprisingly unusual in biotech: $BGNE doesn't use CROs in clinical developmenmt With 3000 internal clin ops folks, it believes their in-house approach is 30% cheaper and 30% faster (enrollment and PoC) than industry benchmarks (thx to Andrew Berens at Leerink)

17

25

203

Bruce Booth

@LifeSciVC

3 years

Atlas loves to back first-time CEOs. Of 45 CEOs in our current active portfolio, 71% of them have never done it before. Similar percentage in our 18 public biotech companies. Taking bets on people by backing first-time CEOs is a huge part of our business

6

197

Bruce Booth

@LifeSciVC

4 years

#FridayFunny My daughter is wonderfully geeky... This morning, while making her bagel, she casually says "Look Dad, my bagel just went through Mi-toast-sis"... #GirlsInSTEM #ScienceIsCool #Science

8

5

198

Bruce Booth

@LifeSciVC

5 years

Our 2019 Year In Review: Macro, Biotech, and Atlas. Macro: History may not repeat itself but it does rhyme. #Biotech : Capital, Collaboration, Community, Culture Atlas: our evolution, portfolio, and team. @atlasventure

AtlasVenture YinR 2019 Youtube B Booth

Atlas Venture partner, biotech venture investor, and LifeSciVC author Bruce Booth shares his Year in Review of 2019. Watch the talk here and visit www.atlasv...

www.youtube.com

17

49

195

Bruce Booth

@LifeSciVC

3 years

Moderna $MRNA has a market cap today of $93B - that's more than the combined valuations of the last 86 biotech IPOs combined. Wow. Helping to bring a global pandemic to an end - incredible value to patients, investors, and the world

6

18

193

Bruce Booth

@LifeSciVC

3 years

The response to my post on empathy today has blown me away. Most read blog post ever. Thank you to the hundreds of people who reached out to me to share life stories & challenges, so wonderfully inspiring & emotional. We're all in this world together, and only once. #Empathy

Bruce Booth

@LifeSciVC

3 years

Personal Reflection: Empathy In The Workplace Life isn't always easy, and many of us have a lot going on underneath the facade, but its the emotional connectedness with others that makes all the difference. To those that have been there for me, thx you

52

59

514

4

9

197

Bruce Booth

@LifeSciVC

7 months

Big Carmot Therapeutics M&A today. Huge kudos to The Column Group. First institutional investor in the deal (bought 60% for $2M in 2012) to build fragment-based drug discovery platform. Invested actively over next 11 yrs TCG owned 40% today or $1.2B+... huge win for them

4

16

195

Bruce Booth

@LifeSciVC

6 years

Taking a break from biotech... Super proud of my Mom - she's competing in the USTA Super Senior National Tennis Championship in Arizona at 79 years old this week! Way to go!

8

3

192

Bruce Booth

@LifeSciVC

4 years

It’s been a crazy long week... market meltdown around COVID, executing on full WFH distancing, crisis mgt in portfolio... Reflecting on the craziness, I’m looking forward to having a Quarantini tonight.

18

197

Bruce Booth

@LifeSciVC

7 months

While biotech has been challenging, there’s still much to be thankful for - esp the great bio community dedicated to “doing well by doing good” bringing Rx's to patients. Feel so very fortunate to work in this industry. Wishes of health, happiness, and gratitude for Thanksgiving.

5

12

194

Bruce Booth

@LifeSciVC

4 years

Record-Breaking Biotech Funding Tsunami Of 1H2020 Largest amount of quarterly VC funding ever. Largest amount raised in biotech IPOs in a quarter. Largest total equity capital raised in a quarter. Hopefully we will make new drugs with it!

6

73

187

Bruce Booth

@LifeSciVC

2 years

Penn State. Class of 2026. So excited for her! We are… Penn State! She apparently knew it 18 years ago #pennstate #psu #weare #nittanylions

9

0

193

Bruce Booth

@LifeSciVC

2 years

Biotech Bears: Jumping A Lower Bar Or A Higher One? A few thoughts on what's behind the negative data slump in #biotech . $XBI $NBI

Biotech Bears: Jumping A Lower Bar Or A Higher One? - LifeSciVC

Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for what...

lifescivc.com

13

36

188

Bruce Booth

@LifeSciVC

4 years

My #JPM20 agenda... ... ... ... and the humming sound of chairlifts. JOMO [Joy of...] Good luck to all of you who are attending. It's a gr8 meeting if you are there for the right reasons: do the deals, court the investors, make it happen! Hopefully it's productive for you!

16

8

185

Bruce Booth

@LifeSciVC

4 years

Biotech is boomin'. Four IPOs last week... raised $900M... all traded well after their opening. Books were well covered, highly concentrated into top 10-20 blue chip buyers - and all were upsized from their initial filings. $LEGN $PLRX $CALT $AMTI

7

41

183

Bruce Booth

@LifeSciVC

2 years

Biotech VC continues apace: at >$1.9B, Feb 2022 was the 2nd highest Feb ever in terms of private biotech VC funding in US, trailing only Feb 2021. While public mkts are very challenging, the long cycle of VC funding for innovation appears more resilient, at least for now

10

19

184

Bruce Booth

@LifeSciVC

1 year

Biotech Funding: Times Are Tough, Maybe For The Better.

13

44

176

Bruce Booth

@LifeSciVC

3 years

Out of pocket drug costs are the issue, caused by a broken insurance/formulary system. Fact: Net insulin prices back to Rx co’s have been falling for yrs in US. The gross-to-net price bubble distorts the discussion. Pharma is an easy target, but lazy & wrong @BernieSanders

Bernie Sanders

@BernieSanders

3 years

Cost to manufacture 1 vial of insulin: Around $6 Cost of 1 vial of insulin for consumers: 🇫🇷: $9 🇩🇪: $11 🇯🇵: $14 🇦🇺: $7 🇬🇧: $7 🇨🇦: $12 🇺🇸: $98 The American people should not be forced to pay the highest prices on the planet for prescription drugs.

2K

14K

74K

15

37

180

Bruce Booth

@LifeSciVC

4 years

I was just talking to my 82-yr old parents about #poliovirus . How scared families were during early 50s epidemic, about getting it at summer swimming pools. R0 ~6 (super infectious) & transmitted via contiminated water, lots of fear. Knew folks being put in iron lungs to breath

Vincent Racaniello

@profvrr

4 years

On this day 65 years ago the first #poliovirus vaccine was licensed in US after an historic clinical trial in 1.8 million children. Do you think we will have similar headlines for #SARSCoV2 vaccine in 2021? Salk inactivated polio vaccine is still in use today! #virology #history

10

289

644

8

49

179

Bruce Booth

@LifeSciVC

6 months

$XBI has just witnessed the best 2-month stretch EVER for the sector It has seen 8 consecutive weeks of gains, up +14% in Nov and +18% more in Dec, or 39% off the Oct lows. Fed rates, M&A boom, good data, cash recycling - all conspiring. thx to Jack Bannister at Leerink

3

32

176

Bruce Booth

@LifeSciVC

5 years

Mega-deal $BMY & $CELG: good news for more big cap M&A speculation, but bad news for private & small-cap names as consolidation removes 1 of the most active buyers/deal-makers. These two bid against each other in many deals in past few years, and that's no longer going to happen

4

42

176

Bruce Booth

@LifeSciVC

4 years

Ashley and I celebrated her day by making a COVID-15th birthday cake, inclusive of viral spike glycoproteins... #BirthdaysInTimeOfCOVID #socialdistancingbirthday

11

3

177

Bruce Booth

@LifeSciVC

3 years

Very proud to be a part of this incredible team at Atlas. Closed our 2nd Opportunity Fund at the hard cap of $300M to support building & scaling our portfolio. Onward & upward!

Michael Forkel

@InHocSigno08

3 years

Atlas Venture announces closing of $300 million second Opportunity Fund to invest growth capital in Atlas-backed biotech companies.

0

3

18

11

3

175

Bruce Booth

@LifeSciVC

6 years

Great @atlasventure holiday party last night! Celebrating 25 years of biotech investing with the broader Atlas family. Had to throw on the first “suit and tie” that I’ve worn in ages as a matching pair with my wife - was good fun. Happy holidays to all!

9

2

171

Bruce Booth

@LifeSciVC

4 years

Another sad impact of #COVID19 "These Kids With Rare Genetic Diseases Were Part Of Research Into New Treatments. The Coronavirus Has Stopped All Of It." via @dvergano

14

77

163

Bruce Booth

@LifeSciVC

2 months

"Pharmacology: The Anchor for Nearly Every Diligence" Part 2 blog from Atlas' @AimeeRaleigh13 and entrepreneur Haojing Rong, covering: - Pharmacokinetics - Pharmacodynamics - Efficacy - Common pitfalls

Pharmacology: The Anchor for Nearly Every Diligence - LifeSciVC

By Haojing Rong and Aimee Raleigh, as part of the From The Trenches feature of LifeSciVC This blog post is the second in a series on key diligence concepts and questions. If you missed the intro blog...

lifescivc.com

3

21

171

Bruce Booth

@LifeSciVC

3 years

Novel targets aren’t often easy to drug. After running a truly gold standard discovery campaign, and advancing the science around Gasdermins, we’ve decided to shut down @QuenchBio . In the thread below, CEO @SamTruex closes the book on this “successful failure”...

7

9

168

Bruce Booth

@LifeSciVC

3 years

Five Macro Risks To Biotech Coming Out of Washington: - Drug pricing - FTC's view of M&A - FDA stance - Interest rates - Tax Policy Key question is how will these resolve & how much the market has already priced in regarding expectations around them.

Five Macro Risks To Biotech Coming Out of Washington - LifeSciVC

Despite saving the world from COVID, pharma and biotech are still in the crosshairs of many politicians. With many anti-Pharma politicians and regulators emboldened in the current environment, and...

lifescivc.com

7

46

165

Bruce Booth

@LifeSciVC

3 years

This rpt from a "friend" of innovative biotech: w/ friends like this, who needs enemies! So many errors in here. Striking lack of insight into how biopharma ecosystem works. M&A promotes innovation by more efficiently allocating capital, talent & ideas:

BioPharma M&A Drives More Efficient Resource Allocation - LifeSciVC

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions get closed...

lifescivc.com

Rep. Katie Porter

@RepKatiePorter

3 years

Today, our office released a bombshell report exposing the devastating effects of Big Pharma’s mergers and acquisitions. Featuring exclusive interviews with former Immunex, and later Amgen employees, our report shows how consolidation curbs innovation at the expense of patients.

182

3K

12K

8

26

167

Bruce Booth

@LifeSciVC

4 years

Twitter stock dropped 21% on Friday, losing ~$8B in market cap... Equal to all of $ proceeds raised by the last 40 or so Biotech IPOs combined... in the midst of biggest biotech IPO boom ever... Biotech is buzzing, but it remains very small piece of the equity markets vs tech

11

26

169

Bruce Booth

@LifeSciVC

7 months

FTC vs Sanofi/Maze: very bad precedent for gov't overreach. And bad in general for patients in all disease areas FTC continues to create friction in the deal mkt that is so vital to our collaborative biotech ecosystem reliant on external innovation

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Statement on FTC challenge to proposed license agreement with Maze Therapeutics Paris, December 11, 2023. Sanofi is disappointed with the Federal Trade...

www.globenewswire.com

13

35

161

Bruce Booth

@LifeSciVC

2 months

"Deconstructing the Diligence Process: An Approach to Vetting New Product Theses" Atlas' @AimeeRaleigh13 opines in a fantastic new blog covering: - Target Validation - Directionality and Druggability - Pharmacology - Path to PoC - Product Opportunity

Deconstructing the Diligence Process: An Approach to Vetting New Product Theses - LifeSciVC

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Ever wondered what goes into diligencing a new idea, program, company, or platform? While each...

lifescivc.com

1

17

166

Bruce Booth

@LifeSciVC

6 years

Single best twitter follow: @AndyBiotech . Content and data-rich, biotech-focused, very high signal-to-noise (unlike most). Awesome. @AndyBiotech Thank you for what you do.

9

19

165

Bruce Booth

@LifeSciVC

3 years

"Immuno-Oncology: The Comeback Kid." - perspective on the progress in I-O from @hotspotthera 's CDO Tim Reilly and CEO Jonathan Montagu, in the latest From The Trenches blog post.

5

31

165

Bruce Booth

@LifeSciVC

7 months

$CERE acquisition by $ABBV for $8.7B Perhaps the best bio SPAC exit ever: up 450% since July 2020 deal with Perceptive's SPAC. Raised $2B in equity since inception Spun out of $PFE by Bain Capital in 2018 Congrats Ron Renaud and the team @biotech1969 !

6

23

160

Bruce Booth

@LifeSciVC

4 years

A must read on a parallel pandemic: DKE-19 “Dunning-Kruger Effect (DKE) is a phenomenon where people lack the ability to understand their lack of ability.” DKE-19 is a virulent misinformation virus that’s exploding

Ninja Economics

@NinjaEconomics

4 years

Flatten the Curve of Armchair Epidemiology

2

33

74

10

73

160

Bruce Booth

@LifeSciVC

6 years

The market for C-level talent for biotech startups is super tight right now (e.g., CFOs with ECM cred, CBOs with sellside deal sheets, CSOs who gone A to Z in drug discovery, CMOs who r translationally-savvy). Probably the biggest constraint on new venture creation and scaling.

16

42

163

Bruce Booth

@LifeSciVC

2 years

In 2010, Top 20 drugs in US treated 45M patients. In 2020, Top 20 only treated 9M patients But revenues up 25% because of prices (more expensive rarer/lower prevalence diseases ) McKinsey at #AtlasVentureRetreat

15

42

159

Bruce Booth

@LifeSciVC

4 years

My youngest just became a teenager today. From toddler to teen overnight it seems. Crazy. Time flies. HBD, Henry!

8

0

160

Bruce Booth

@LifeSciVC

4 months

$VKTX's obesity data is impressive and it's now a $7B+ market cap. Great case study in R&D success. But it's also a great case study in dilution. Today its a $7B+ mkt cap at $72/share. In 2015, Viking's IPO raised $24M at $8/share, with a post-money of ~$75M Mkt cap

15

18

161

Bruce Booth

@LifeSciVC

11 months

What a journey at LLY... Wow... $LLY adds like $75B this morning on GLP1 MACE data. In Aug 2013, stock was ~$50... now >$500. 10x in a decade. Not your typical large cap pharma stock

10

15

160

Bruce Booth

@LifeSciVC

5 years

Two days ago I put out a blog on #JPM19 that i wrote quickly on a flight and wasn’t even sure people would read. Apparently it struck a chord & went viral. Most read & commented on blog I’ve ever written, out of 300+ posts... So hard to predict these things.

10

12

157

Bruce Booth

@LifeSciVC

6 years

Autumn morning in the White Mountains of NH. Stunning.

5

9

158

Bruce Booth

@LifeSciVC

3 years

Very proud Dad moment today: my daughter Ashley crushed 66K vertical feet over 40 miles on her snowboard at Loon Mtn... breaking my record... kind of insane. Love it. #Snowboard #SkiNH #SkiTheEast @loonmtn

14

0

157

Bruce Booth

@LifeSciVC

5 years

Recycling of M&A capital is important for refueling younger biotech's: $LLY's $LOXO acquisition ($8B) returns more cash to investors than was raised by all 60 biotech IPOs in 2018 ($7.1B). #JPM19 $XBI

5

50

158

Bruce Booth

@LifeSciVC

1 month

When a biotech company says its lead program is “ready for Phase 1” but hasn’t yet filed an IND, doesn’t that mean it’s in what most of us call the Preclinical Development phase?

FierceBiotech

@FierceBiotech

1 month

J&J is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology meds including a phase 1-ready asset that targets TSLP. $JNJ

1

6

19

36

9

155

Bruce Booth

@LifeSciVC

4 years

Monday AM reflection: spent the wknd skiing w/ 2 boys w/ Duchenne, carving up the slopes together. For those working on DMD cures, keep at it: these boys need you! More broadly, we need all of you to conquer the medical mountains ahead by staying focused on patients! #JPM20

4

8

153

Bruce Booth

@LifeSciVC

10 months

Today we said goodbye to JB, taken from us far too soon, even for DMD. His passion for life was so inspiring. He changed my life, and many others, in such a positive wonderful way. Rest in peace, buddy.

20

0

153

Bruce Booth

@LifeSciVC

2 years

Biotech Fund Flows: Largest week of fund inflows in ~16 months. And 3rd consecutive positive week for the sector. #biotech (thx Piper Sandler for sharing metrics from Lipper/AMG Data Services)

6

21

153

Bruce Booth

@LifeSciVC

3 years

Biotech Funding Tops The Charts Again... with reflections and questions about the discipline of its deployment.

Biotech Funding Tops The Charts Again - LifeSciVC

Another quarter, another set of all-time highs for biotech funding – and this surfeit of capital continues raises possible concerns about its disciplined deployment. Back in January, when reflecting...

lifescivc.com

8

37

150

Bruce Booth

@LifeSciVC

2 years

Biotech’s January Chill: Big Drop In New Startups. January 2022 saw the lowest number of new first round financings (new startups) in over a decade Includes discussion of the talent constraint on startup, including the debate of too many vs too few co's

14

38

155

Bruce Booth

@LifeSciVC

4 years

Strategic Planning In Biotech During A Pandemic Crisis. This is the Goldilocks moment for many biotechs: not too hot and not too cold. Preserving near term optionality while planning for and adapting to the longer term scenarios.

6

50

151

Bruce Booth

@LifeSciVC

4 years

A 19-year journey at $MNTA. Founded in '01, seeded by @polarisvc at $1/share, @atlasventure led B in '03 at $2.95, IPO'd at $6.50 in '04, bought by J&J at $52.50. Story changed over yrs from Enox to FcRN. Nipocalimab now looks like a great drug, thx to persistence of the team!

7

8

154

Bruce Booth

@LifeSciVC

1 year

Sadly, this tweet didn’t age well… Looks like a fear-driven “run on the bank” has destroyed a once great financial institution…. FDIC Receivership wasn’t fathomable only a few days ago…. Took 40 years to build a great brand, 48 hrs to wipe it out.

Bruce Booth

@LifeSciVC

1 year

💯 agree with Mark Take a deep breath. @SVB_Financial is a great long term partner for the startup ecosystem. Any financial risk is way oversold here, real risk is contagion. Reality: SVB has liquidity, passes stress tests, has a low loan to capital ratio. Stay calm.

16

18

128

39

23

150

Bruce Booth

@LifeSciVC

2 years

Lots of speculation that after 12 month downdraft in $XBI that private mkt would "slow-down"... As of mid-Feb, 1Q22 is tracking to be the biggest Q for VC funding in #biotech of all time Over $7B in first 6 wks. Needs to get >$11B for trophy; might not, but still huge funding

18

34

151

Bruce Booth

@LifeSciVC

3 years

Great piece, @John_LaMattina Hidden gem: healthcare provider giving a few minute vaccine injection (& paperwork) gets paid $80 for the two visits, while the vaccine innovator gets $39. That's a striking contrast when you think of where the actual "value" is...

John LaMattina

@John_LaMattina

3 years

Hospital Costs, Not Drug Prices, Are Out Of Control via @forbes

13

42

148

8

29

152

Bruce Booth

@LifeSciVC

2 years

Surprising Resilience Of Private VC-Backed Biotech Markets 2022 is off to fastest start for VC financings than every year except '21 Over $6B has been invested in 2Q 2022 far more than 2Q in all but 2020-'21 June 2022 was also huge, 2nd biggest ever

Surprising Resilience Of Private VC-Backed Biotech Markets - LifeSciVC

It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years. Nothing like this pullback has happened in recent...

lifescivc.com

8

34

150

Bruce Booth

@LifeSciVC

1 year

Payroll coming next week, many startups have funds locked up with SVB FDIC VCs are going to need to bridge with simple loans to cover near-term working capital Syndicates need to fully participate in helping here. Big reputation blackmark for those investors that don’t step up

10

23

149

Bruce Booth

@LifeSciVC

3 years

I now have an 18 year kid. An adult. Wow. How did this happen? Happy birthday @evibooth !

8

0

147

Bruce Booth

@LifeSciVC

2 years

The joy of being a seed investor: the hard work of nurturing the winners, while eliminating the weeds, converts into a rewarding harvest - real pharm to table! Plus having one’s hands in the earth is truly therapeutic.

9

1

150

Bruce Booth

@LifeSciVC

2 years

In Defense Of Early Stage Biotech IPOs An open permissive IPO mkt, and the flow of capital that enables it, has been a huge positive for the #biotech sector & for advancing innovation, and is not what caused the current $XBI pullback Warning: long read

In Defense Of Early Stage Biotech IPOs - LifeSciVC

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. I’ve read a good deal of venting covering...

lifescivc.com

12

25

150

Bruce Booth

@LifeSciVC

5 months

Fundraising by VCs was very strong in 2023, raising $19B for health-related funds. In past three years, ~$70B in new funds were raised. That's a TON of "dry powder" that will get put to work into startups over the next 2-5 years #SVBHealthcare @SiliconVlyBank #biotech

5

33

149

Bruce Booth

@LifeSciVC

5 years

Biotech Startups And The Hard Truth Of Innovation. A practitioner's (long-winded) reflections on Gary Pisano's excellent article on innovative cultures.

9

63

142

Bruce Booth

@LifeSciVC

3 years

Melee in the biotech capital markets: 10 Biotech IPOs are supposed to price this week! $SANA, $IMCR, $BOLT, $VOR, $PHVS, $SNSE, $TERN, $LABP, $ANGN, $EVAX 1st week in Feb is usually a busy week (2 wks after JPM, b4 financials go stale), but this is crazy busy! Raising $1.5B+

7

31

148

Bruce Booth

@LifeSciVC

4 years

Understanding population-level immunity via serology testing seems like such a critically important yet blind spot right now. Big difference in policy solutions if it's 0.5% vs 5% vs 25% of the adult population that has acquired immunity. Right now does anyone really know?

16

32

148

Bruce Booth

@LifeSciVC

4 months

Excellent report: Guggenhiem's ADC Landscape deep dive by Michael Schimdt and his team. 11 FDA-approved ADCs, expected to sell $28B in 2030 95 ADC programs active in clinical development today ~50% use Microtubule toxic payloads, 30% TOPOi

1

20

145

Bruce Booth

@LifeSciVC

3 years

My afternoon Instacart #fail Just wanted 6 bananas… 🤣🤣

37

0

147